Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Apr;35 Suppl 1(Suppl 1):35-39.
doi: 10.37201/req/s01.08.2022. Epub 2022 Apr 22.

Ceftolozane-tazobactam in nosocomial pneumonia

F J Candel  1 , J González Del Castillo, A Julián Jiménez, M Matesanz
Affiliations
Review

Ceftolozane-tazobactam in nosocomial pneumonia

F J Candel et al. Rev Esp Quimioter. 2022 Apr.

Erratum in

Abstract

Ceftolozane is a potent antimicrobial against Pseudomonas aeruginosa, including carbapenem-resistant and multidrug-resistant strains, and is also active against Enterobacteriaceae. It MIC (minimal inhibitory concentration) and MPC (mutant preventive concentration) are close together, allowing to avoid the mutant selection window specifically in the treatment of Pseudomonas aeruginosa infection. The molecule is time-dependent and stable when reconstituted at room temperature, facilitating safe and effective dosage optimization in frail and critically ill patients. It has been shown to be non-inferior to meropenem in the treatment of nosocomial infection in the ASPECT-NP study but superior in post-hoc studies in the subgroup of patients with ventilator-associated pneumonia, without the emergence of resistance during treatment. It is FDA approved at a dose of 3 g every 8 hours in the treatment of nosocomial pneumonia (HABP/VABP) in adults.

PubMed Disclaimer

Conflict of interest statement

Authors declare no conflicts of interest

Figures

Figure 1
Figure 1
Structure–activity relationships for ceftolozane
Figure 2
Figure 2
The gate of the 3-side chain binding pocket of AmpC b-lactamase and the chain of ceftolozane approaching (modified from reference 2)
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Zhanel GG, Chung P, Adam H, Zelenitsky S, Denisuik A, Schweizer F, et al. . Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant Gram-negative bacilli. Drugs. 2014; 74(1): 31-51. - PubMed
    1. Murano K, Yamanaka T, Toda A, Ohki H, Okuda S, Kawabata K, et al. . Structural requirements for the stability of novel cephalosporins to AmpC beta-lactamase based on 3D-structure. Bioorg Med Chem. 2008; 16 (5): 2261-75 - PubMed
    1. Yahav D, Giske CG, Grāmatniece A, Abodakpi H, Tam VH, Leibovici L. New β-Lactam–β-Lactamase Inhibitor Combinations. Clin Microbiol Rev 2020;34(1): e00115-20 - PMC - PubMed
    1. Carvalhaes CG, Castanheira M, Sader HS, Flamm RK, Shortridge D. 2019. Antimicrobial activity of ceftolozane–tazobactam tested against gramnegative contemporary (2015–2017) isolates from hospitalized patients with pneumonia in US medical centers. Diagn Microbiol Infect Dis 94:93–102. - PubMed
    1. Sader HS, Farrell DJ, Castanheira M, Flamm RK, Jones RN. Antimicrobial activity of ceftolozane/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011–12). J Antimicrob Chemother 2014; 69: 2713–2722. - PubMed